Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.50 |
| ▸ | HTR2B | P41595 | 9/20 | 0.50 |
| ▸ | HTR2A | P28223 | 8/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262930 | 0.82 | HTR2C (0.44) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL18600524 | 0.76 | KMT2A (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL4430749 | 0.74 | HTR2C (0.49) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL28059226 | 0.71 | PLD1 (0.48) | HTR2CHTR2BHTR2A | |
| SCHEMBL27955445 | 0.70 | ADRB1 (0.47) | HTR2CHTR2BHTR2AHTR6TACR1 | |
| SCHEMBL2404066 | 0.69 | HTR2C (0.54) | HTR2CHTR2BHTR2ATACR1 | |
| SCHEMBL27856999 | 0.69 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL5631228 | 0.68 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6NOTUM | |
| SCHEMBL5632309 | 0.68 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6NOTUM | |
| SCHEMBL5631221 | 0.68 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | HTR2C 2851/4885HTR2B 2497/4885HTR2A 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.